At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported that the Early ...

At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, SAB Biotherapeutics presented Phase 1 ...

Merging high-potency and green chemistry expertise, Indena and TCG GreenChem are setting new global standards in ...

The API and drug product facility is the first of four new manufacturing plants set to be built by Eli Lilly in the US over ...

At EASD 2025, investigators reported one-year outcomes from a study of zimislecel (VX-880), an allogeneic, stem cell-derived ...

VarmX has established a partnership with CSL for the development of VMX-C001, designed to aid in restoring blood coagulation ...

GSK has announced a $30bn investment in the US over the next five years in research and development (R&D) and supply chain.

The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.

Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral ...

Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased a sweeping array of advancements in the ...

Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors to expand its anticoagulation ...

Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.